Protease production by clinical isolates of type III group B streptococci

D. C. Straus, S. J. Mattingly, T. W. Milligan, T. I. Doran, T. J. Nealon

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Abstract

Six strains of serotype III group B streptococci isolated from confirmed cases of neonatal disease were examined for their ability to produce proteolytic enzymes. Three neuraminidase-producing strains and three non-neuraminidase-producing strains were employed in this study. Protease production was examined in 1,000-fold concentrated filtrates of stationary-phase cells with an insoluble substrate derived from horse hide powder labeled covalently with Remazol brilliant blue. Protease activity was not detected in any cultural supernatant fluids until they were fractioned on Sephadex G-100. After fractionation, the neuraminidase-producing strains were shown to elaborate approximately sixfold more protease than the non-neuraminidase-producing strains. The finding that clinical isolates of group B streptococci that elaborated high levels of neuraminidase also produced elevated levels of extracellular protease may indicate that the production of several different factors may determine the virulence of these organisms.

Original languageEnglish (US)
Pages (from-to)421-425
Number of pages5
JournalJournal of clinical microbiology
Volume12
Issue number3
DOIs
StatePublished - 1980

ASJC Scopus subject areas

  • Microbiology (medical)

Fingerprint

Dive into the research topics of 'Protease production by clinical isolates of type III group B streptococci'. Together they form a unique fingerprint.

Cite this